{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.5005","value":"69.402"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"}],"units":"Participants"}],"title":"Day 28: Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.9949","value":"63.529"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Day 28: Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.6257","value":"74.779"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"title":"Day 28: Rash"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.6437","value":"66.011"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"title":"Day 28: Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.7208","value":"71.684"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"Day 28: Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.6621","value":"68.834"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"}],"units":"Participants"}],"title":"Day 56: Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.2859","value":"65.327"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"title":"Day 56: Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.7506","value":"70.016"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"title":"Day 56: Rash"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.4007","value":"61.626"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Day 56: Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.9064","value":"65.980"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"Day 56: Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"64.6462","value":"81.269"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"}],"units":"Participants"}],"title":"Day 84: Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.6674","value":"71.585"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"title":"Day 84: Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.5237","value":"89.080"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Day 84: Rash"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.6179","value":"77.702"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"title":"Day 84: Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.3041","value":"86.949"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Day 84: Vomiting"}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"}],"units":"Participants"}],"description":"An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to maximum severity grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Grade 1= mild; Grade 2= moderate; within normal limits, Grade 3= severe or medically significant but not immediately life-threatening; Grade 4= life-threatening or disabling; urgent intervention indicated; Grade 5= death. Trough plasma concentration of participants who had grade 1 or higher AE are presented in this outcome measure. Data of plasma concentration is reported separately for each preferred term of AE.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Philadelphia chromosome-positive CML received bosutinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG000","title":"Bosutinib"}],"paramType":"MEAN","populationDescription":"PK population included all enrolled participants who received at least 1 dose of bosutinib and had sufficient plasma results available. Here, \"N\" signifies number of participants evaluable for this outcome measure and \"n\" signifies participants evaluable at specified time points only. Data for this outcome measure was not planned to be collected and analyzed for Imatinib arm as pre-specified in the protocol.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Days 28, 56 and 84","title":"Summary of Trough Plasma Concentration by Presence of Grade 1 or Higher Adverse Events (AEs) of Bosutinib","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"ng/mL"}